Based on the Neurocrine Biosciences Inc stock forecast from 19 analysts, the average analyst target price for Neurocrine Biosciences Inc is USD 162.82 over the next 12 months. Neurocrine Biosciences Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Neurocrine Biosciences Inc is Slightly Bullish , which is based on 10 positive signals and 5 negative signals. At the last closing, Neurocrine Biosciences Inc’s stock price was USD 110.87. Neurocrine Biosciences Inc’s stock price has changed by -3.15% over the past week, -6.68% over the past month and -20.01% over the last year.
No recent analyst target price found for Neurocrine Biosciences Inc
No recent average analyst rating found for Neurocrine Biosciences Inc
Company Overview Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy and schizophrenia; NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California. Read Less
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Hunti...Read More
Frequently Asked Questions About Neurocrine Biosciences Inc (NBIX) Stock
Based on ratings from 19 analysts Neurocrine Biosciences Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 29 buy, sell and 4 hold ratings.
Unfortunately we do not have enough data on NBIX's stock to indicate if its a good dividend stock.
Based on targets from 19 analysts, the average taret price for NBIX is USD 162.82 over the next 12 months. The maximum analyst target price is USD 192 while the minimum anlayst target price is USD 114.
NBIX stock's Price/Earning ratio is 36.09.
Our analysis grades NBIX stock's Price / Earning ratio at F. This means that NBIX stock's Price/Earning ratio is above 55.00000000000001% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the NSD exchange.
Based on this NBIX may be a overvalued for its sector.
The last closing price of NBIX's stock was USD 110.87.
The most recent market capitalization for NBIX is USD 11.84B.
Based on targets from 19 analysts, the average taret price for NBIX is projected at USD 162.82 over the next 12 months.
This means that NBIX's stock price may go up by +46.86% over the next 12 months.
We can't find any ETFs which contains Neurocrine Biosciences Inc's stock.
As per our most recent records Neurocrine Biosciences Inc has 1,800 Employees.
Neurocrine Biosciences Inc's registered address is 12780 El Camino Real, San Diego, CA, United States, 92130.
You can get more information about it from Neurocrine Biosciences Inc's website at https://www.neurocrine.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Neurocrine Biosciences Inc (NBIX) Stock
Based on ratings from 19 analysts Neurocrine Biosciences Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 29 buy, sell and 4 hold ratings.
Unfortunately we do not have enough data on NBIX's stock to indicate if its a good dividend stock.
Based on targets from 19 analysts, the average taret price for NBIX is USD 162.82 over the next 12 months. The maximum analyst target price is USD 192 while the minimum anlayst target price is USD 114.
NBIX stock's Price/Earning ratio is 36.09.
Our analysis grades NBIX stock's Price / Earning ratio at F. This means that NBIX stock's Price/Earning ratio is above 55.00000000000001% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the NSD exchange.
Based on this NBIX may be a overvalued for its sector.
The last closing price of NBIX's stock was USD 110.87.
The most recent market capitalization for NBIX is USD 11.84B.
Based on targets from 19 analysts, the average taret price for NBIX is projected at USD 162.82 over the next 12 months.
This means that NBIX's stock price may go up by +46.86% over the next 12 months.
We can't find any ETFs which contains Neurocrine Biosciences Inc's stock.
As per our most recent records Neurocrine Biosciences Inc has 1,800 Employees.
Neurocrine Biosciences Inc's registered address is 12780 El Camino Real, San Diego, CA, United States, 92130.
You can get more information about it from Neurocrine Biosciences Inc's website at https://www.neurocrine.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for NBIX !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
